FDA approves Merck’s WINREVAIR for treatment of pulmonary arterial hypertension

WINREVAIR is a breakthrough biologic for this rare, progressive disease

Lupin Life hosted Second Edition of Aptivate Champion Run for Kids

The Aptivate Champion Run witnessed an enthusiastic participation of over 4,000 Mumbaikars

Lupin receives USFDA’s approval or Propranolol Hydrochloride Extended-Release Capsules USP

Lupin receives tentative approval from USFDA for Dapagliflozin and Saxagliptin tablets

Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US

Healthcare Triangle completes US$2 million private placement debt offering

The company received gross proceeds of approximately US$1.7 million and net proceeds,

Inspira Technologies closes on $3.88 million RDO

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering

Innovent and SanegeneBio collaborate to develop siRNA drug for treatment of hypertension

Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908

Elpiscience and Astellas collaborate for novel bispecific macrophage engager

Elpiscience will receive up to US $37 million, including the upfront payment and license option fees

Lupin receives tentative USFDA approval for Sitagliptin Tablets

Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus

Granules India received ANDA approval for Sildenafil for oral suspension

The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million